Safety of Extending The Routine Flushing Of Implanted Port Devices From 4 Weeks To 12
NCT05454189 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400
Last updated 2026-05-20
Summary
Implanted port devices (IPD) play an essential role in the safe administration of cancer treatments by providing a device to safely administer caustic chemotherapy agents. The current recommended frequency of flushing the IPD per manufacturers guidelines is every 4-6 weeks. The purpose of this study is to find out if extending IPD flushes to every 12 weeks is safe and if it is just as effective as every 4 week flushing.
Conditions
- Maintenance of Implanted Port Devices
Interventions
- DEVICE
-
Reduced IPD Flush Schedule
IPD flush every 12 weeks
- DEVICE
-
Standard IPD Flush Schedule
IPD flush every 4 weeks
Sponsors & Collaborators
-
Minnesota Cancer Clinical Trials Network
collaborator UNKNOWN -
Essentia Health
lead OTHER
Principal Investigators
-
Bret Friday, MD, PhD · Essentia Health
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-10-11
- Primary Completion
- 2025-07-01
- Completion
- 2026-12-31
- FDA Device
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors
NCT03035409 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Glufosfamide With of Without Hydration in Treating Patients With Advanced Non-small Cell Lung Cancer
NCT00005055 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer
NCT00059943 ·Status: COMPLETED ·Phase: PHASE2
-
Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia
NCT00102661 ·Status: COMPLETED ·Phase: PHASE2
-
Improving the Safety of Fluoropyrimidine-based Chemotherapy
NCT04194957 ·Status: UNKNOWN ·Phase: NA
-
Osteosarcoma1999-A Study Of Intensive Chemotherapy for Osteosarcoma
NCT00145639 ·Status: COMPLETED ·Phase: PHASE2
-
Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer
NCT00033345 ·Status: COMPLETED ·Phase: PHASE1
-
A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer
NCT00421135 ·Status: COMPLETED ·Phase: PHASE1
-
Non-Invasive Neurosensory Testing For Chemotherapy-Induced Peripheral Neuropathy
NCT03909464 ·Status: COMPLETED
-
Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer
NCT06671613 ·Status: RECRUITING ·Phase: NA
-
α-TEA in Advanced Cancer
NCT02192346 ·Status: COMPLETED ·Phase: PHASE1
-
Supportive Care Delivered by Telemedicine to Cancer Patients at Home
NCT04136340 ·Status: COMPLETED ·Phase: NA
-
An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer
NCT04733534 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Microvascular Function in Patients Undergoing 5-Fluorouracil Chemotherapy
NCT04042298 ·Status: COMPLETED
-
Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.
NCT00426140 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines
NCT02324452 ·Status: COMPLETED ·Phase: NA
-
Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
NCT00387504 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies
NCT01290380 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection
NCT00001339 ·Status: COMPLETED ·Phase: PHASE2
-
Benzoylphenylurea in Treating Patients With Advanced Solid Tumors
NCT00016354 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor
NCT04122118 ·Status: COMPLETED ·Phase: NA
-
The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC
NCT04170959 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
NCT02828930 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Ketoconazole Inhibition of CYP3A on Urinary Excretion of Docetaxel
NCT00697437 ·Status: COMPLETED ·Phase: PHASE2
-
Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study
NCT04260269 ·Status: ENROLLING_BY_INVITATION